News Medical on MSN
Calcium-sensitive switch boosts the efficacy of cancer drugs
Cancer-fighting antibody drugs are designed to penetrate tumor cells and release a lethal payload deep within, but too often ...
Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell ...
As bispecifics, ADCs, protein degraders, and AI-designed mini-proteins move into the clinic, discovery teams face a new ...
Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for ...
Dr. Charles M. Rudin highlighted new small cell lung cancer therapies, including T cell engagers, antibody-drug conjugates, ...
Discusses New Strategy and Business Plan Focused on Commercialization and Liquid Biopsy Innovation November 26, 2025 9:00 ...
News-Medical.Net on MSN
Novel therapy reduces tumor growth in models of triple-negative breast cancer
Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer (TNBC), which is among the most aggressive and ...
With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...
Kelun Biotech's sac-TMT plus Merck's Keytruda shows significant progress in late-stage lung cancer trial. Read more here.
GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.
November 2025 saw pivotal FDA approvals, including durvalumab for gastric cancers and pembrolizumab/enfortumab vedotin for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback